Financials BioGaia AB

Equities

BIOG B

SE0017769995

Pharmaceuticals

Market Closed - Nasdaq Stockholm 11:29:35 2024-04-26 am EDT 5-day change 1st Jan Change
115.2 SEK +1.23% Intraday chart for BioGaia AB -3.60% +13.83%

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025
Capitalization 1 7,359 10,846 10,462 8,439 10,219 11,633 -
Enterprise Value (EV) 1 7,145 9,378 8,977 6,951 8,665 10,378 10,671
P/E ratio 39.3 x 53.3 x 53.3 x 22.6 x 28 x 28.9 x 26.6 x
Yield 0.88% 0.64% 0.7% 1.74% 1.88% 5.99% 5.99%
Capitalization / Revenue 9.58 x 14.5 x 13.3 x 7.64 x 7.88 x 8.18 x 7.38 x
EV / Revenue 9.3 x 12.6 x 11.4 x 6.3 x 6.68 x 7.29 x 6.77 x
EV / EBITDA 27.7 x 37.7 x 31.9 x 18 x 18.5 x 20.1 x 18.8 x
EV / FCF 61,844,893 x 45,704,120 x 41,657,791 x - - - -
FCF Yield 0% 0% 0% - - - -
Price to Book 14.5 x 5.49 x 5.57 x 4.28 x 5.03 x 6.7 x 7.87 x
Nbr of stocks (in thousands) 86,682 100,982 100,982 100,982 100,982 100,982 -
Reference price 2 84.90 107.4 103.6 83.57 101.2 115.2 115.2
Announcement Date 2/6/20 2/4/21 2/4/22 2/3/23 2/7/24 - -
1SEK in Million2SEK
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025
Net sales 1 768.3 747.1 785.1 1,104 1,297 1,423 1,576
EBITDA 1 258.1 248.7 281 385.3 468.4 517.6 568.4
EBIT 1 242.5 228.2 253.7 361.5 443.1 491.3 540.7
Operating Margin 31.56% 30.54% 32.31% 32.74% 34.18% 34.52% 34.3%
Earnings before Tax (EBT) 1 242.3 227.6 252.7 447.6 468.8 516.4 560.6
Net income 1 187.3 179.7 196.3 373.6 365.4 402.8 437.2
Net margin 24.38% 24.05% 25% 33.84% 28.18% 28.31% 27.74%
EPS 2 2.162 2.014 1.944 3.700 3.620 3.990 4.330
Free Cash Flow 115.5 205.2 215.5 - - - -
FCF margin 15.04% 27.46% 27.45% - - - -
FCF Conversion (EBITDA) 44.76% 82.51% 76.69% - - - -
FCF Conversion (Net income) 61.69% 114.18% 109.78% - - - -
Dividend per Share 2 0.7500 0.6820 0.7260 1.450 1.900 6.900 6.900
Announcement Date 2/6/20 2/4/21 2/4/22 2/3/23 2/7/24 - -
1SEK in Million2SEK
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q2 2022 Q3
Net sales 1 173.8 206.2 288.1 257.7
EBITDA 1 73.43 58.22 107.4 98.85
EBIT 1 67.18 53.1 101.3 93.74
Operating Margin 38.64% 25.75% 35.16% 36.37%
Earnings before Tax (EBT) 1 66.94 52.63 99 98.8
Net income 1 52.84 38.3 78.54 79.5
Net margin 30.4% 18.57% 27.26% 30.85%
EPS 2 0.5240 0.3800 0.7800 0.7900
Dividend per Share - - - -
Announcement Date 10/21/21 2/4/22 7/22/22 10/21/22
1SEK in Million2SEK
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025
Net Debt 1 - - - - - - -
Net Cash position 1 214 1,468 1,485 1,488 1,554 1,255 962
Leverage (Debt/EBITDA) - - - - - - -
Free Cash Flow 116 205 215 - - - -
ROE (net income / shareholders' equity) 37% 16% 10.8% 19.4% 18.3% 21.4% 27.2%
ROA (Net income/ Total Assets) - - - - - - -
Assets 1 - - - - - - -
Book Value Per Share 2 5.860 19.60 18.60 19.50 20.10 17.20 14.60
Cash Flow per Share 1.710 2.190 2.200 - - - -
Capex 1 32.3 16.1 6.38 17.9 48.6 35 36.8
Capex / Sales 4.21% 2.15% 0.81% 1.62% 3.75% 2.46% 2.33%
Announcement Date 2/6/20 2/4/21 2/4/22 2/3/23 2/7/24 - -
1SEK in Million2SEK
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
115.2 SEK
Average target price
140 SEK
Spread / Average Target
+21.53%
Consensus